170015-99-3

Basic information

• Product Name: 4-(Trifluoromethoxy)phenylethyl amine
• Synonyms: 4-(Trifluoromethoxy)phenylethyl amine;4-(Trifluoromethoxy)phenethylamine
• CAS NO: 170015-99-3
• Molecular Formula: C₉H₁₀F₃NO
• Molecular Weight: 205.1770096
• Product Categories: Fluorine series
• Mol File: 170015-99-3.mol

Chemical Properties

• Boiling Point: 211℃
• Flash Point: 81℃
• Appearance: /
• Density: 1.233
• Vapor Pressure: 0.187mmHg at 25°C
• Refractive Index: 1.471
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.60±0.10(Predicted)
• CAS DataBase Reference: 4-(Trifluoromethoxy)phenylethyl amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Trifluoromethoxy)phenylethyl amine(170015-99-3)
• EPA Substance Registry System: 4-(Trifluoromethoxy)phenylethyl amine(170015-99-3)

Safety Data

• Hazardous Substances Data: 170015-99-3(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry and Drug Development:
4-(Trifluoromethoxy)phenylethyl amine is used as a building block for the development of new pharmaceuticals, leveraging its unique structure and functional groups to create compounds with desired properties for therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(Trifluoromethoxy)phenylethyl amine is used as a key intermediate for the synthesis of various organic compounds, contributing to the creation of molecules with specific characteristics and functions.
Used in Agrochemical Development:
4-(Trifluoromethoxy)phenylethyl amine is used as a fluorinated building block in the development of agrochemicals, where its trifluoromethoxy group can enhance the properties and stability of the resulting products, improving their effectiveness in agricultural applications.
Used in Material Science:
In material science, 4-(Trifluoromethoxy)phenylethyl amine is utilized for the development of materials with enhanced properties, such as improved stability and performance, thanks to the presence of the trifluoromethoxy group.

InChI:InChI=1/C9H10F3NO/c10-9(11,12)14-8-3-1-7(2-4-8)5-6-13/h1-4H,5-6,13H2

Upstream product

• 49561-96-8 (4-trifluoromethoxy-phenyl)-acetonitrile 
• 898271-42-6 2-[4-(trifluoromethoxy)phenyl]acetamide 

Downstream Products

• 199678-26-7 C₁₁H₉F₆NO₂ 
• 245651-69-8 6-(1-chloroethyl)-5-iodo-4-[2-(4-trifluoromethoxyphenyl)ethylamino]pyrimidine 
• 170015-32-4 flufenerim 
• 1443151-82-3 4-chloro-6-methoxy-N-{2-[4-(trifluoromethoxy)phenyl]ethyl}-1,3,5-triazin-2-amine 
• 1365761-97-2 ethyl 4-(trifluoromethoxy)phenethylcarbamate 
• 1334406-59-5 trifluoromethanesulfonic acid 2-methoxy-6-[2-(4-trifluoromethoxyphenyl)ethylamino]pyrimidin-4-yl ester 

Relevant articles and documents

17a-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS

The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of the formula I: I(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

PROCESS FOR PREPARING 2-(4-TRIFLUOROMETHOXYPHENYL)ETHYLAMINE AND 4-BROMOMETHYL-AND 4-CHLOROMETHYL-1-TRIFLUOROMETHOXYBENZENE

The invention relates to a process for preparing 2-(4-trifluoromethoxyphenyl)ethylamine in an advantageous manner by (a) converting trifluoromethoxybenzene by halomethylation into halogenomethyl-1-trifluoromethoxybenzene, (b) converting the halogenomethyl

Process for preparing phenethylamines and novel chemical compounds

Fluorine-containing phenethylamines are obtained in an advantageous manner by reacting fluorine-containing bromobenzenes with acrylamide in the presence of a palladium catalyst, hydrogenating the resulting arylacrylamides catalytically and then rearrangin

Process for preparing fluorine-containing phenethylamines and novel fluorine-containing β-iminovinyl-and β-iminoethylbenzenes

The present invention relates to a process for preparing fluorine-containing phenethylamines which is characterized in that, in a first step, a substituted bromobenzene is reacted with an N-vinylimide in the presence of a palladium catalyst, in a second step, the resulting substituted β-iminovinylbenzene is hydrogenated catalytically and in a third step, the substituted β-iminovinylbenzene obtained in the second step is cleaved. This process also provides access to novel β-iminovinyl- and β-iminoethylbenzenes.